Abstract
Abstract The findings of the Heart and Estrogen/Progestin Replacement Study (HERS) and the Women's HealthInitiative (WHI) astonished researchers and physicians—and struck fear in the hearts of postmenopausal women. Both studies had been expected to show benefits from hormone replacement therapy (HRT). 1–3 It was anticipated that estrogen/progestin therapy would reduce or prevent coronary heart disease (CHD) in women and provide other symptomatic benefits during menopause. As a result of the 2 studies, estrogen/progestin therapy was considered risky rather than beneficial, and was largely abandoned. Now, however, Naftolin and 13 colleagues from across the United States 4 have challenged those concerns by shedding light on the flaws of the HERS and the WHI study, which have been confirmed by Rivera-Woll and Davis. 5
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
